Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 2
2015 1
2016 1
2017 2
2018 4
2019 3
2020 11
2021 9
2022 9
2023 13
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Results by year

Filters applied: . Clear all
Page 1
Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study GFPC 06-2018.
Bylicki O, Tomasini P, Radj G, Guisier F, Monnet I, Ricordel C, Bigay-Game L, Geier M, Chouaid C, Daniel C, Swalduz A, Toffart AC, Doubre H, Peloni JM, Moreau D, Subtil F, Grellard JM, Castera M, Clarisse B, Martins-Lavinas PH, Decroisette C, Greillier L; GFPC. Bylicki O, et al. Among authors: ricordel c. Eur J Cancer. 2023 Apr;183:38-48. doi: 10.1016/j.ejca.2023.01.014. Epub 2023 Jan 31. Eur J Cancer. 2023. PMID: 36801605 Free article. Clinical Trial.
Newly identified tumor suppressor functions of ING proteins.
Heliez L, Ricordel C, Becuwe P, Pedeux R. Heliez L, et al. Among authors: ricordel c. Curr Opin Pharmacol. 2023 Feb;68:102324. doi: 10.1016/j.coph.2022.102324. Epub 2022 Dec 13. Curr Opin Pharmacol. 2023. PMID: 36521226 Free article. Review.
ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironment.
Ponce S, Cedrés S, Ricordel C, Isambert N, Viteri S, Herrera-Juarez M, Martinez-Marti A, Navarro A, Lederlin M, Serres X, Zugazagoitia J, Vetrhus S, Jaderberg M, Hansen TB, Levitsky V, Paz-Ares L. Ponce S, et al. Among authors: ricordel c. J Immunother Cancer. 2023 Sep;11(9):e007552. doi: 10.1136/jitc-2023-007552. J Immunother Cancer. 2023. PMID: 37661097 Free PMC article. Clinical Trial.
Characterization of 164 patients with NRAS mutated non-small cell lung cancer (NSCLC).
Dehem A, Mazieres J, Chour A, Guisier F, Ferreira M, Boussageon M, Girard N, Moro-Sibilot D, Cadranel J, Zalcman G, Ricordel C, Wislez M, Munck C, Poulet C, Gauvain C, Descarpentries C, Wasielewski E, Cortot AB, Baldacci S. Dehem A, et al. Among authors: ricordel c. Lung Cancer. 2023 Dec;186:107393. doi: 10.1016/j.lungcan.2023.107393. Epub 2023 Oct 9. Lung Cancer. 2023. PMID: 37839252 Free article.
Danazol Treatment for Telomere Diseases.
Jouneau S, Kerjouan M, Ricordel C. Jouneau S, et al. Among authors: ricordel c. N Engl J Med. 2016 Sep 15;375(11):1095. doi: 10.1056/NEJMc1607752. N Engl J Med. 2016. PMID: 27626530 No abstract available.
Safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination in stage IV non-small-cell lung cancer: An open-label phase II trial (VinMetAtezo).
Vergnenegre A, Monnet I, Ricordel C, Bizieux A, Curcio H, Bernardi M, Corre R, Guisier F, Hominal S, Le Garff G, Bylicki O, Locher C, Geier M, Chouaïd C, Robinet G; GFPC team. Vergnenegre A, et al. Among authors: ricordel c. Lung Cancer. 2023 Apr;178:191-197. doi: 10.1016/j.lungcan.2023.02.020. Epub 2023 Feb 27. Lung Cancer. 2023. PMID: 36868180 Clinical Trial.
51 results